Determination of disk diffusion and MIC quality control parameters for AZD2563, a novel long-acting oxazolidinone

Diagnostic Microbiology and Infectious Disease

Volumn 45, Issue 1, 2003, Pages 73-76

  Anderegg, Tamara R ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXAZOLIDINONE DERIVATIVE; POSIZOLID; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; ENTEROCOCCUS FAECALIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

DIFFUSION; DRUG RESISTANCE, MICROBIAL; ENTEROCOCCUS FAECALIS; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0037309815     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(02)00482-0     Document Type: Article

References (11)

1. Anderegg T.R., Biedenbach D.J., Jones R.N. In vitro evaluation of AZD2563, a new oxazolidinone, tested against β-haemolytic and viridans group streptococci. J Antimicrob Chemother. 49:2002;1019-1021.
2. Anderegg T.R., Biedenbach D.J., Jones R.N. In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates. Antimicrob Agents Chemother. 46:2002;2662-2664.
3. Arundel, P. A. (2001). The new oxazolidinone, AZD2563: Physiologically-based pharmacokinetic extrapolation to man. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Abst. F-1039, p. 226. American Society for Microbiology, Washington, DC.
4. Craig, W. A., & Andes, D. R. (2001). Pharmacodynamic characteristics of AZD2563, the new oxazolidinone, in a murine thigh-infection model. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Abst. F-1037, p. 226. American Society for Microbiology, Washington, DC.
5. Diekema D.J., Jones R.N. Oxazolidinone antibiotics. Lancet. 358:2001;1975-1982.
6. Gravestock, M. B., Betts, M. J., Chawner, E., Dawson, L., McGregor, A., & Mills, S. D. (2001). In vivo studies of novel oxazolidinones with O- and N-linked C-5 heterocyclic side-chains, including AZD2563. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Abst. F-1023, p. 222. American Society for Microbiology, Washington, DC.
7. Jones R.N., Biedenbach D.J., Anderegg T.R. In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual Gram-positive species. Diagn Microbiol Infect Dis. 42:2002;119-122.
8. National Committee for Clinical Laboratory Standards. (2000a). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5. Wayne, PA: NCCLS.
9. National Committee for Clinical Laboratory Standards. (2000b). Performance standards for antimicrobial disk susceptibility tests, seventh edition. Approved standard M2-A7. Wayne, PA: NCCLS.
10. National Committee for Clinical Laboratory Standards. (2001). Development of in vitro susceptibility testing criteria and quality control parameters, second edition. Approved standard M23-A2. Wayne, PA: NCCLS.
11. National Committee for Clinical Laboratory Standards. (2002). Performance standards for antimicrobial susceptibility testing. Approved standard M100-S12. Wayne, PA: NCCLS.